19043 research outputs found
Sort by
Loss-Of-Function G6PD Variant Moderated High-Fat Diet-Induced Obesity, Adipocyte Hypertrophy, and Fatty Liver in Male Rats
Obesity is a major risk factor for liver and cardiovascular diseases. However, obesity-driven mechanisms that contribute to the pathogenesis of multiple organ diseases are still obscure and treatment is inadequate. We hypothesized that increased , glucose-6-phosphate dehydrogenase (G6PD), the key rate-limiting enzyme in the pentose shunt, is critical in evoking metabolic reprogramming in multiple organs and is a significant contributor to the pathogenesis of liver and cardiovascular diseases. G6PD is induced by a carbohydrate-rich diet and insulin. Long-term (8 months) high-fat diet (HFD) feeding increased body weight and elicited metabolic reprogramming in visceral fat, liver, and aorta, of the wild-type rats. In addition, HFD increased inflammatory chemokines in visceral fat. Interestingly, CRISPR-edited loss-of-function Mediterranean G6PD variant (G6PD) rats, which mimic human polymorphism, moderated HFD-induced weight gain and metabolic reprogramming in visceral fat, liver, and aorta. The G6PD variant prevented HFD-induced CCL7 and adipocyte hypertrophy. Furthermore, the G6PD variant increased Magel2 - a gene encoding circadian clock-related protein that suppresses obesity associated with Prader-Willi syndrome - and reduced HFD-induced non-alcoholic fatty liver. Additionally, the G6PD variant reduced aging-induced aortic stiffening. Our findings suggest G6PD is a regulator of HFD-induced obesity, adipocyte hypertrophy, and fatty liver
InTouch Week of October 28, 2024
Medical Students Run for Charity at the 2024 TCS New York City Marathon NYMC Goes Pink for Breast Cancer Awareness Month Furry Friends Bring Comfort to the College Faculty Spotlight: From Pupil to Professor: Alumni Lighting the Way at NYMC Student Spotlight: AMA Foundation Physicians of Tomorrow Scholarship Recipienthttps://touroscholar.touro.edu/in_touch/1339/thumbnail.jp